- Our Suppliers
- MBS Monoclonals
- Chlamydia sp. LPS Antibody
Product short description
Price:
790 EUR
Size:
500ug
Catalog no.:
GEN605688
Product detailed description
Gene name
N/A
Gene name synonims
N/A
Other gene names
N/A
Concentration
N/A
Other names
N/A
Immunoglobulin isotype
IgG2b
Clone
10B2222
French translation
anticorps
Disease
chlamydia
Category
Antibodies
Clonality
Monoclonal
Tested applications:
ELISA (EL/EIA)
Also known as
Chlamydia sp. LPS
Subcategory
Mnoclonal antibodies
Host organism
Mouse (Mus musculus)
Purification method
Highly Purified by Ion Exchange chromatography.
Additional disease
Cervix, urethra an eye infection by Chlamydia trachomatis can form inclusion bodies in humans.
Form/Appearance
Supplied as a lyophilized powder from PBS. No preservative added. Reconstitute with 500ul sterile ddH2O.
Properties
If you buy Antibodies supplied by MBS Monoclonals they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.
Species reactivity
N/A; Due to limited knowledge and inability for testing each and every species, the reactivity of the antibody may extend to other species which are not listed hereby.
Specificity and cross-reactivity
Recognizes Chlamydia lipopolysaccharide. Has not been cross-adsorbed and may react with LPS from related species. ; Since it is not possible to test each and every species our knowledge on the corss reactivity of the antibodies is limited. This particular antibody might cross react with speacies outside of the listed ones.
Storage and shipping
Lyophilized powder may be stored the antibody should be stored at -20 degrees Celsius.. Stable for 12 months the antibody should be stored at -20 degrees Celsius.. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. For optimal long term storage, the antibody should be kept at -20 degrees Celsius. Reconstituted product is stable for 12 months the antibody should be stored at -20 degrees Celsius.. Prior to use, briefly centrifuge the original vial after thawing and before lid. If further dilution(s) are needed, they can be done with the appropriate assay buffer.
Gene
Bacterial pathogen lipopolysaccharides (LPS) are the major outer surface membrane components present in almost all Gram-negative bacteria and act as extremely strong stimulators of innate or natural immunity in diverse eukaryotic species ranging from insects to humans. LPS consist of a poly- or oligosaccharide region that is anchored in the outer bacterial membrane by a specific carbohydrate lipid moiety termed lipid A. The lipid A component is the primary immunostimulatory center of LPS. With respect to immunoactivation in mammalian systems, the classical group of strongly agonistic (highly endotoxin) forms of LPS has been shown to be comprised of a rather similar set of lipid A types. In addition, several natural or derivative lipid A structures have been identified that display comparatively low or even no immunostimulation for a given mammalian species. Some members of the latter more heterogeneous group are capable of antagonizing the effects of strongly stimulatory LPS/lipid A forms. Agonistic forms of LPS or lipid A trigger numerous physiological immunostimulatory effects in mammalian organisms, but--in higher doses--can also lead to pathological reactions such as the induction of septic shock. Cells of the myeloid lineage have been shown to be the primary cellular sensors for LPS in the mammalian immune system. During the past decade, enormous progress has been obtained in the elucidation of the central LPS/lipid A recognition and signaling system in mammalian phagocytes. According to the current model, the specific cellular recognition of agonistic LPS/lipid A is initialized by the combined extracellular actions of LPS binding protein (LBP), the membrane-bound or soluble forms of CD14 and the newly identified Toll-like receptor 4 (TLR4)*MD-2 complex, leading to the rapid activation of an intracellular signaling network that is highly homologous to the signaling systems of IL-1 and IL-18. The elucidation of structure-activity correlations in LPS and lipid A has not only contributed to a molecular understanding of both immunostimulatory and toxic septic processes, but has also re-animated the development of new pharmacological and immuno-stimulatory strategies for the prevention and therapy of infectious and malignant diseases.
© Copyright 2016-Tech News . Design by: uiCookies